HPV-16 | Total | P value | ||
---|---|---|---|---|
Negative | Positive | |||
Gender | ||||
Female | 58 (82.9%) | 12 (17.1%) | 70 (46.7%) | 0.564 |
Male | 66 (82.5%) | 14 (17.5%) | 80 (53.3%) | |
Age group | ||||
1–30 years | 2 (33.3%) | 4 (66.7%) | 6 (4.0%) | 0.002 |
31–60 years | 104 (86.7%) | 16 (13.3%) | 120 (80.0%) | |
61–90 years | 18 (75.0%) | 6 (25.0%) | 24 (16.0%) | |
Cancer diagnosis | ||||
Esophageal SCC | 26 (65.0%) | 14 (35.0%) | 40 (26.7%) | 0.001 |
Nasopharyngeal carcinoma | 30 (100%) | 0 (0.0%) | 30 (20.0%) | |
Tongue | 14 (77.8%) | 4 (22.2%) | 18 (12.0%) | |
Conjunctiva SCC | 18 (100%) | 0 (0.0%) | 18 (12.0%) | |
Mucoepidermoid carcinoma | 6 (100%) | 0 (0.0%) | 6 (4.0%) | |
Adenoid cystic carcinoma | 4 (66.7%) | 2 (33.3%) | 6 (4.0%) | |
Myoepithelial carcinoma | 6 (100%) | 0 (0.0%) | 6 (4.0%) | |
Lips SCC | 8 (100%) | 0 (0.0%) | 8 (5.3%) | |
Larynx | 6 (50.0%) | 6 (50.0%) | 12 (8.0%) | |
Oropharyngeal carcinoma | 6 (4.0%) | 0 (0.0%) | 6 (4.0%) | |
Total | 124 (82.7%) | 26 (17.3%) | 150 (100%) |